Special Issue "Recent Advances in Thyroid Cancer Research"
Deadline for manuscript submissions: 31 December 2021.
Interests: cancer; cell biology; gravitational biology; space medicine; tissue engineering; pharmacology; apoptosis; SOX transcription factors
Special Issues and Collections in MDPI journals
Special Issue in International Journal of Molecular Sciences: Cell and Molecular Biology of Thyroid Disorders
Special Issue in International Journal of Molecular Sciences: Multikinase Inhibitors and Cancer
Special Issue in International Journal of Molecular Sciences: Cell and Molecular Biology of Thyroid Disorders 2.0
Special Issue in International Journal of Molecular Sciences: Microgravity and Space Medicine
Special Issue in International Journal of Molecular Sciences: Microgravity and Space Medicine 2.0
Thyroid cancer (TC) comprises malignant tumours of the thyroid gland. TC is classified into several categories: first, differentiated tumors covering papillary, follicular and Hürthle cell cancer; second, medullary; and third, anaplastic TC. The American Cancer Society’s most recent estimates for TC in the US for 2021 are: 1. About 44,280 new cases (12,150 in men and 32,130 in women) and 2. about 22,200 deaths (1,050 men and 1,150 women). The most common type is the papillary thyroid carcinoma, with a share of 80–90% in all TC.
In recent years, studies in the field of TC have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option for both differentiated and medullary TC. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in phase III trials. Most of them produced a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic, radioiodine (RAI)-refractory TC.
In this Special Issue, studies using animal or cell culture models to investigate molecular mechanisms of TC will be published. This Special Issue will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy.
Prof. Dr. Daniela Grimm
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Thyroid cancer
- Cell Biology
- OMICS investigations
- Cell Signaling
- Tyrosine kinase inhibitors
- Molecular biology
- In vitro studies
- Animal studies
- Drug testing